☆ 4.6 Article

In vitro Activity of Cefiderocol and Comparators against Carbapenem-Resistant Gram-Negative Pathogens from France and Belgium

ANTIBIOTICS-BASEL (2022)

Related references

Note: Only part of the references are listed.

Article Immunology

Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamase-Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized Studies

Jean-Francois Timsit et al.

Summary: The CREDIBLE-CR and APEKS-NP studies showed that cefiderocol treatment is effective against gram-negative bacteria producing metallo-B-lactamases, with favorable rates of clinical cure, microbiological eradication, and all-cause mortality compared to other treatment options.

CLINICAL INFECTIOUS DISEASES (2022)

Add to Collection

Article Infectious Diseases

European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)

Mical Paul et al.

Summary: These guidelines address the targeted antibiotic treatment of 3GCephRE and carbapenem-resistant Gram-negative bacteria, focusing on the effectiveness of individual antibiotics and on combination versus monotherapy. Most recommendations are based on low-certainty evidence.

CLINICAL MICROBIOLOGY AND INFECTION (2022)

Add to Collection

Article Infectious Diseases

All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies

Thomas P. Lodise et al.

Summary: Pathogen-focused, randomized, controlled trials (PF-RCT) are crucial in the fight against carbapenem-resistant Gram-negative infections. Recent studies have investigated both new and older generic antibiotics in a variety of infections. However, PF-RCTs pose challenges due to heterogeneity in infection types, pathogens, and study design. Interpretation of data is further complicated by the lack of statistical analysis plans and limited power. While new antibiotics showed potential in reducing all-cause mortality in CR Enterobacterales infections, combinations of older generic antibiotics did not demonstrate the same effect in CR Acinetobacter spp. infections. More high-quality PF-RCTs are needed to evaluate the clinical benefit of drug-resistant infections.

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2022)

Add to Collection

Article Medicine, General & Internal

Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis

Christopher J. L. Murray et al.

Summary: Antimicrobial resistance (AMR) poses a significant threat to global human health, and this study provides the most comprehensive estimates of AMR burden to date. By estimating deaths and disability-adjusted life-years (DALYs) associated with bacterial AMR in 204 countries and territories in 2019, the study highlights the impact of resistance and the leading pathogen-drug combinations contributing to it.

LANCET (2022)

Add to Collection

Article Pharmacology & Pharmacy

Successful prolonged treatment of a carbapenem-resistant Acinetobacter baumannii hip infection with cefiderocol: A case report

Lucia Rose et al.

Summary: We present a case of a 50-year-old Caucasian male with complex medical history who developed extensive polymicrobial osteomyelitis, including a carbapenem-resistant Acinetobacter baumannii (CRAB). The patient received compassionate use of cefiderocol for 6 weeks with no adverse reactions and achieved cure of the infection.

PHARMACOTHERAPY (2022)

Add to Collection

Article Infectious Diseases

Assessment of In Vitro Cefiderocol Susceptibility and Comparators against an Epidemiologically Diverse Collection of Acinetobacter baumannii Clinical Isolates

Clara Balleste-Delpierre et al.

Summary: This study investigated the in vitro antimicrobial activity of cefiderocol and other antibiotics against a diverse collection of Acinetobacter baumannii clinical isolates, revealing cefiderocol and colistin as the most active agents. Notably, cefiderocol demonstrated superior efficacy against multidrug-resistant and carbapenem-resistant A. baumannii isolates, suggesting it as a promising alternative treatment option for infections caused by these strains.

ANTIBIOTICS-BASEL (2022)

Add to Collection

Article Infectious Diseases

Outcomes with Cefiderocol Treatment in Patients with Bacteraemia Enrolled into Prospective Phase 2 and Phase 3 Randomised Clinical Studies

David L. Paterson et al.

Summary: The analysis of three clinical studies on cefiderocol suggests that it may be an effective treatment option for gram-negative bacterial infections, including pathogens resistant to other antibiotics.

INFECTIOUS DISEASES AND THERAPY (2022)

Add to Collection

Article Immunology

Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa)

Pranita D. Tamma et al.

Summary: This article provides updated guidance on the treatment of infections caused by ESBL-E, CRE, and DTR-P. aeruginosa. The guidance was developed by a panel of infectious diseases specialists and includes preferred and alternative treatment recommendations. The document emphasizes the importance of consulting with an infectious diseases specialist for the treatment of antimicrobial-resistant infections.

CLINICAL INFECTIOUS DISEASES (2022)

Add to Collection

Article Microbiology

Emergence of High-Level Cefiderocol Resistance in Carbapenem-Resistant Klebsiella pneumoniae from Bloodstream Infections in Patients with Hematologic Malignancies in China

Peng Lan et al.

Summary: Cefiderocol-resistant CRKP strains are emerging in Chinese patients with hematologic malignancies. The resistance is mediated by multiple factors including the deficiency of CirA, metallo- or serine-beta-lactamases, and can be further enhanced by NDM expression and CirA deficiency. This poses challenges to the clinical efficacy of cefiderocol in the future.

MICROBIOLOGY SPECTRUM (2022)

Add to Collection

Review Microbiology

Klebsiella pneumoniae Carbapenemase Variants Resistant to Ceftazidime-Avibactam: an Evolutionary Overview

Claire Amaris Hobson et al.

Summary: This review describes the mutational landscape of KPC beta-lactamase towards ceftazidime-avibactam resistance, showing that resistance is associated with three hot spots and a high representation of insertions and deletions compared to other beta-lactamases. The extension of resistance to ceftazidime-avibactam is accompanied by a trade-off in resistance to other beta-lactams and a decrease in enzyme stability. The natural stability of KPC could explain its propensity to acquire in vivo mutations conferring resistance to ceftazidime-avibactam.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)

Add to Collection

Review Microbiology

Cefiderocol Antimicrobial Susceptibility Testing Considerations: the Achilles' Heel of the Trojan Horse?

Patricia J. Simner et al.

Summary: Cefiderocol is a novel siderophore-conjugated cephalosporin that shows activity against multidrug-resistant Gram-negative bacilli. It utilizes a siderophore component to bind iron and enter bacterial cells, leading to cell death. Further clinical studies are needed to determine its effectiveness against other organisms.

JOURNAL OF CLINICAL MICROBIOLOGY (2021)

Add to Collection

Article Immunology

Cefiderocol as Rescue Therapy for Acinetobacter baumannii and Other Carbapenem-resistant Gram-negative Infections in Intensive Care Unit Patients

Marco Falcone et al.

Summary: In this study, cefiderocol was used to treat patients with bacteremia or ventilator-associated pneumonia caused by drug-resistant strains, showing a 70% clinical success rate and 90% survival rate. However, two patients experienced microbiological failure, highlighting the need for future prospective studies to further evaluate the effectiveness of the treatment.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Article Microbiology

KPC-39-Mediated Resistance to Ceftazidime-Avibactam in a Klebsiella pneumoniae ST307 Clinical Isolate

Agnes B. Jousset et al.

Summary: Resistance to the combination of ceftazidime (CAZ) and avibactam (AVI) is increasing, with a CAZ-AVI-resistant Klebsiella pneumoniae strain reported here. This strain, belonging to the high-risk sequence type 307 (ST307) clone, produces Klebsiella pneumoniae carbapenemase 39 (KPC-39), a single-amino-acid variant of KPC3. The study found that KPC-39 has lost carbapenemase activity but shows increased affinity for CAZ, suggesting potential silent dissemination in European healthcare settings.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)

Add to Collection

Article Infectious Diseases

Cross-resistance to cefiderocol and ceftazidime-avibactam in KPC β-lactamase mutants and the inoculum effect

Claire Amaris Hobson et al.

Summary: This study reveals that CZA-resistant KPC variants may lead to cross-resistance to cefiderocol by increasing the MICs. Additionally, cefiderocol is greatly impacted by the inoculum effect, indicating precautions should be taken when treating infections with suspected high inoculum levels.

CLINICAL MICROBIOLOGY AND INFECTION (2021)

Add to Collection

Article Infectious Diseases

In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014-2018 studies in France

Thierry Naas et al.

Summary: In recent years, France has seen an increase in infections caused by carbapenem-resistant Gram-negative pathogens. The study found that cefiderocol demonstrated high in vitro susceptibility rates against a wide range of Gram-negative pathogens, including meropenem-resistant strains, and was significantly more active than comparators against pneumonia isolates.

JAC-ANTIMICROBIAL RESISTANCE (2021)

Add to Collection

Article Immunology

Emergence and Polyclonal Dissemination of OXA-244-Producing Escherichia coli, France

Cecile Emeraud et al.

Summary: Since 2016, OXA-244-producing Escherichia coli has been increasingly isolated in France. Sequencing of 97 OXA-244-producing E. coli isolates revealed a wide diversity of sequence types with a high prevalence of sequence type 38. Long-read sequencing confirmed the chromosomal location of bla(OXA-244) within the entire or truncated Tn51098.

EMERGING INFECTIOUS DISEASES (2021)

Add to Collection

Article Infectious Diseases

Longitudinal analysis of ESBL and carbapenemase carriage among Enterobacterales and Pseudomonas aeruginosa isolates collected in Europe as part of the International Network for Optimal Resistance Monitoring (INFORM) global surveillance programme, 2013-17

Krystyna M. Kazmierczak et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)

Add to Collection

Article Infectious Diseases

Emerging extensively drug-resistant bacteria (eXDR) in France in 2018

M. Colomb-Cotinat et al.

MEDECINE ET MALADIES INFECTIEUSES (2020)

Add to Collection

Article Multidisciplinary Sciences

Impact of anticancer chemotherapy on the extension of beta-lactamase spectrum: an example with KPC-type carbapenemase activity towards ceftazidime-avibactam

Claire Amaris Hobson et al.

SCIENTIFIC REPORTS (2020)

Add to Collection

Article Microbiology

In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, against Multidrug-Resistant Gram-Negative Bacteria

Shazad Mushtaq et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)

Add to Collection

Article Infectious Diseases

Cefiderocol for compassionate use in the treatment of complicated infections caused by extensively and pan-resistant Acinetobacter baumannii

Alessandra Oliva et al.

JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2020)

Add to Collection

Article Infectious Diseases

In vitro activity of the siderophore cephalosporin, cefiderocol, against molecularly characterized, carbapenem-non-susceptible Gram-negative bacteria from Europe

Christopher Longshaw et al.

JAC-ANTIMICROBIAL RESISTANCE (2020)

Add to Collection

Article Infectious Diseases

Worsening epidemiological situation of carbapenemase-producing Enterobacteriaceae in Europe, assessment by national experts from 37 countries, July 2018

Alma Brolund et al.

EUROSURVEILLANCE (2019)

Add to Collection

Review Microbiology

Infections Caused by Carbapenem-Resistant Enterobacteriaceae: An Update on Therapeutic Options

Chau-Chyun Sheu et al.

FRONTIERS IN MICROBIOLOGY (2019)

Add to Collection

Article Microbiology

OXA-48-Mediated Ceftazidime-Avibactam Resistance Is Associated with Evolutionary Trade-Offs

Christopher Frohlich et al.

MSPHERE (2019)

Add to Collection

Article Infectious Diseases

Unravelling ceftazidime/avibactam resistance of KPC-28, a KPC-2 variant lacking carbapenemase activity

Saoussen Oueslati et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)

Add to Collection

Article Immunology

Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria

Patrice Nordmann et al.

CLINICAL INFECTIOUS DISEASES (2019)

Add to Collection

Review Microbiology

New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections

Burcu Isler et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)

Add to Collection

Article Infectious Diseases

In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015

James A. Karlowsky et al.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)

Add to Collection

Article Infectious Diseases

Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis

Alessandro Cassini et al.

LANCET INFECTIOUS DISEASES (2019)

Add to Collection

Article Infectious Diseases

Stability and low induction propensity of cefiderocol against chromosomal AmpC beta-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae

Akinobu Ito et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)

Add to Collection

Article Microbiology

In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria

Akinobu Ito et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)

Add to Collection

Review Immunology

Clinical and laboratory considerations for the rapid detection of carbapenem-resistant Enterobacteriaceae

Ritu Banerjee et al.

VIRULENCE (2017)

Add to Collection

Article Infectious Diseases

Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens

J. Dobias et al.

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2017)

Add to Collection

Article Microbiology

In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study)

Meredith A. Hackel et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)

Add to Collection

Article Microbiology

In Vitro Antimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains

Naoki Kohira et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)

Add to Collection

Article Infectious Diseases

In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria

Akinobu Ito et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)

Add to Collection

Article Microbiology

Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against Pseudomonas aeruginosa

Akinobu Ito et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)

Add to Collection

Article Microbiology

Stability of Novel Siderophore Cephalosporin S-649266 against Clinically Relevant Carbapenemases

Tsukasa Ito-Horiyama et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)

Add to Collection

Article Microbiology

Global Dissemination of blaKPC into Bacterial Species beyond Klebsiella pneumoniae and In Vitro Susceptibility to Ceftazidime-Avibactam and Aztreonam-Avibactam

Krystyna M. Kazmierczak et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)

Add to Collection

Article Microbiology

In Vitro Susceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014)

Boudewijn L. M. de Jonge et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)

Add to Collection

Review Pharmacology & Pharmacy

A review on colistin nephrotoxicity

Atefeh Ordooei Javan et al.

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2015)

Add to Collection

Review Microbiology

Carbapenems: Past, Present, and Future

Krisztina M. Papp-Wallace et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)

Add to Collection

Article Immunology

Carbapenem-Resistant Enterobacteriaceae: Epidemiology and Prevention

Neil Gupta et al.

CLINICAL INFECTIOUS DISEASES (2011)

Add to Collection

Article Immunology

Global Spread of Carbapenemase-producing Enterobacteriaceae

Patrice Nordmann et al.

EMERGING INFECTIOUS DISEASES (2011)

Add to Collection

Article Infectious Diseases

Global spread of carbapenem-resistant Acinetobacter baumannii

Paul G. Higgins et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)

Add to Collection

Review Public, Environmental & Occupational Health

Pseudomonas aeruginosa: a formidable and ever-present adversary

K. G. Kerr et al.

JOURNAL OF HOSPITAL INFECTION (2009)

Add to Collection

© Peeref 2019-2024. All rights reserved.